Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Kornacker

Nurse Practitioner, Family Tampa, FL Nurse Practitioner

NPI 1043753726 CMS profile 10886851

6216 E Sligh Ave, Tampa, FL 33617

Open in the dashboard

General payments

$15,856

676 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Kornacker of Tampa, FL is reported in the CMS Open Payments database as having received $15,856 across 676 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,555 190
2024 General $3,672 155
2023 General $3,899 175
2022 General $3,658 152
2021 General $72 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Kornacker
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Lauren Kornacker were reported at $4,555. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Lauren Kornacker Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $72 $124 $35–$379 $132
2022 $3,658 $141 $44–$430 $149
2023 $3,899 $154 $49–$476 $160
2024 $3,672 $165 $51–$504 $164
2025 $4,555 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $2,429 132 payments
  2. AstraZeneca Pharmaceuticals LP $1,966 80 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,728 78 payments
  4. Genzyme Corporation $1,042 33 payments
  5. Grifols USA, LLC $902 31 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $826 30 payments
  7. Jazz Pharmaceuticals Inc. $608 22 payments
  8. Regeneron Healthcare Solutions, Inc. $607 19 payments
  9. ANI Pharmaceuticals, Inc. $582 21 payments
  10. Amgen Inc. $574 32 payments
  11. Other $4,591 198 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,742 674 payments
  2. Education $114 2 payments
Products named General payments · program years 2021–2025
  1. GLASSIA $1,698 77 payments
  2. TRELEGY ELLIPTA $1,412 87 payments
  3. DUPIXENT Immunology $1,042 33 payments
  4. NUCALA $998 44 payments
  5. Prolastin-C Liquid $902 31 payments
  6. BREZTRI $797 25 payments
  7. FASENRA $722 29 payments
  8. TEZSPIRE $673 22 payments
  9. XYWAV $575 20 payments
  10. DUPIXENT Inflammation And Immunology $540 17 payments
  11. Other $7,059 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

676 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record